aav2/5 optirpe65
Gene therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02781480)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Retinoid isomerohydrolaseSupplementation
RPE65 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aav2/5 optirpe65
- aav2/5-optirpe65
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02946879 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | GTx, Syne Qua Non Limited, University of London |
| NCT02781480 | Phase 1 | Apr 1, 2016 | GTx |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GTx | For profit | 2 | 2 | 2 | 2016 |
| Syne Qua Non Limited | For profit | 1 | 0 | 1 | 2016 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1